is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for pain and inflammation. The Company's lead product, its topical diclofenac patch, recently reported positive Phase II results and plans to initiate the patch Phase III development program in 1Q 2009. Cerimon is financed by the premier investors, MPM, Normura Phase4 and OrbiMed Advisors.
For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.
'/>"/>SOURCE Cerimon Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing2.
Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum3.
Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call4.
Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals5.
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug6.
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals7.
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference8.
Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference9.
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results10.
Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin11.
WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals